GNI Group (TYO:2160) said its subsidiary Gyre Therapeutics has begun dosing in a Phase 1 trial of F230, a treatment candidate for pulmonary arterial hypertension (PAH), in China, according to a Wednesday filing on the Tokyo Stock Exchange.
F230, a selective endothelin A receptor antagonist originally developed by Eisai, was licensed to GNI in 2020. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers.
GNI said the move expands Gyre's fibrosis-focused pipeline, which includes lead drug Hydronidone, into cardiovascular disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。